The invention relates to pyrimidinone derivatives of the general Formula I, ##STR00001## or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

The invention relates to pyrimidinone derivatives of the general Formula I, ##STR00001## or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and/or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and/or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

##STR00001##

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

##STR00001##

The present disclosure features useful methods to treat cancer, e.g., in a subject in need thereof. The methods described herein are useful in the treatment of disorders associated with GRK2 expression, e.g., cancer or cardiovascular disease. The present disclosure also features compounds (e.g., GRK2 inhibitors), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof.

In the present invention, a method for producing a compound of formula I comprises a step for causing a compound of formula III to undergo a Pechmann condensation reaction with respect to a compound of formula II in the presence of an organic solvent and an acid catalyst to obtain a compound of formula IV, and due to such method, provided are a novel photoreactive compound and a method for producing same that can be used for nucleic acid photoreaction technology.

In the present invention, a method for producing a compound of formula I comprises a step for causing a compound of formula III to undergo a Pechmann condensation reaction with respect to a compound of formula II in the presence of an organic solvent and an acid catalyst to obtain a compound of formula IV, and due to such method, provided are a novel photoreactive compound and a method for producing same that can be used for nucleic acid photoreaction technology.

The invention relates to chemistry and pharmacology, specifically to a synthetic biologically active substance -7,9-dibromo-2,4-dioxo-1,2,3,4-tetrahydrochromeno[2,3-d]-pyrimidinium-10 acetate or succinate formula 1:1

##STR00001## Where X.sup.−═CH.sub.3COO.sup.− or HOOCCH.sub.2CH.sub.2COO.sup.−, as well as its tautomeric, hydrated forms, solvate, complex compounds, adducts and salt forms, possessing antimicrobial activity, and the ability to penetrate bacterial biofilms. The compound is intended for the treatment of bacterial infections of the oropharynx, skin, and mucous membranes, urinary system, implants, respiratory system, gastrointestinal tract. osteomyelitis, sepsis, nosocomial and wound infections.

The invention relates to chemistry and pharmacology, specifically to a synthetic biologically active substance -7,9-dibromo-2,4-dioxo-1,2,3,4-tetrahydrochromeno[2,3-d]-pyrimidinium-10 acetate or succinate formula 1:1

##STR00001## Where X.sup.−═CH.sub.3COO.sup.− or HOOCCH.sub.2CH.sub.2COO.sup.−, as well as its tautomeric, hydrated forms, solvate, complex compounds, adducts and salt forms, possessing antimicrobial activity, and the ability to penetrate bacterial biofilms. The compound is intended for the treatment of bacterial infections of the oropharynx, skin, and mucous membranes, urinary system, implants, respiratory system, gastrointestinal tract. osteomyelitis, sepsis, nosocomial and wound infections.